Journal List > Tuberc Respir Dis > v.81(3) > 1099585

Kim, Kim, Jo, Eom, Mok, Kim, Park, Lee, and Lee: Predicting Mortality in Patients with Tuberculous Destroyed Lung Receiving Mechanical Ventilation

Abstract

Background

Patients with acute respiratory failure secondary to tuberculous destroyed lung (TDL) have a poor prognosis. The aim of the present retrospective study was to develop a mortality prediction model for TDL patients who require mechanical ventilation.

Methods

Data from consecutive TDL patients who had received mechanical ventilation at a single university-affiliated tertiary care hospital in Korea were reviewed. Binary logistic regression was used to identify factors predicting intensive care unit (ICU) mortality. A TDL on mechanical Ventilation (TDL-Vent) score was calculated by assigning points to variables according to β coefficient values.

Results

Data from 125 patients were reviewed. A total of 36 patients (29%) died during ICU admission. On the basis of multivariate analysis, the following factors were included in the TDL-Vent score: age ≥65 years, vasopressor use, and arterial partial pressure of oxygen/fraction of inspired oxygen ratio <180. In a second regression model, a modified score was then calculated by adding brain natriuretic peptide. For TDL-Vent scores 0 to 3, the 60-day mortality rates were 11%, 27%, 30%, and 77%, respectively (p<0.001). For modified TDL-Vent scores 0 to ≥3, the 60-day mortality rates were 0%, 21%, 33%, and 57%, respectively (p=0.001). For both the TDL-Vent score and the modified TDL-Vent score, the areas under the receiver operating characteristic curve were larger than that of other illness severity scores.

Conclusion

The TDL-Vent model identifies TDL patients on mechanical ventilation with a high risk of mortality. Prospective validation studies in larger cohorts are now warranted.

Introduction

Tuberculous destroyed lung (TDL) results from inadequate treatment of pulmonary tuberculosis and progressive destruction of one or both lungs1. In Korea, TDL is a common cause of pulmonary disability and respiratory failure, and the reported mortality rate is as high as 61%2. A previous study by Ryu et al.3 revealed that TDL was an independent predictor of mortality in patients with acute respiratory failure requiring mechanical ventilation.
Several studies aimed to identify factors predicting mortality in TDL patients24. Park et al.2 evaluated a cohort of 38 TDL patients requiring mechanical ventilation due to acute respiratory failure. The authors found that a positive acid-fast bacilli (AFB) smear or culture was associated with a higher mortality rate, while a higher arterial partial pressure of carbon dioxide (PaCO2) level was associated with increased survival. Ryu et al.4 evaluated 169 patients with TDL and found that extensive lung destruction was the only independent predictor of reduced survival, although only 50 patients (30%) in the cohort had required mechanical ventilation. Acute respiratory failure secondary to TDL is associated with high rates of intensive care unit (ICU) admission, which may burden the limited resources of developing countries56. Early identification of patients with a high risk of mortality, and the selection of individuals who might benefit from ICU care, would therefore facilitate health care planning. However, no scoring system for mortality risk is available for TDL patients on mechanical ventilation.
The aims of the present retrospective study were to (1) develop a mortality prediction model termed the TDL on mechanical Ventilation (TDL-Vent) score using clinical variables obtained at the time of ICU admission; and (2) compare the ability of the TDL-Vent score to predict mortality with that of two widely used illness severity scores.

Materials and methods

1. Study design and cohort

The study was conducted at the Pusan National University Hospital, which is a 1,100-bed university-affiliated hospital in Busan, Korea. Data from consecutive TDL patients who had been admitted to the medical ICU for mechanical ventilation between January 2005 and December 2016 were analyzed. Patients with destroyed lung secondary to other causes were excluded. The primary study outcome was ICU mortality. Secondary outcomes were duration of mechanical ventilation, tracheostomy during ICU stay, length of ICU and total hospital stay, and in-hospital, 28-day, and 60-day mortality. The study protocol was approved by the Institutional Review Board of Pusan National University Hospital (C-1708-028-058). The requirement for informed consent was waived, since the study was retrospective and all patient records were anonymized and de-identified prior to analysis.

2. Data collection and definitions

Baseline demographic and clinical characteristics included age, sex, body mass index, smoking status, comorbidities, and the major diagnosis leading to mechanical ventilation. Disease severity was assessed using the Acute Physiology and Chronic Health Evaluation (APACHE) II score7 and the Sequential Organ Failure Assessment (SOFA) score8. Clinical status within 24 hours of ICU admission (i.e., vasopressor use, renal replacement therapy, and active infections) was also assessed. Laboratory data included complete blood cell count, blood chemistry, and arterial blood gas analysis. Baseline chest X-ray and/or computed tomography scans from the day of ICU admission were reviewed to evaluate the degree of parenchymal lung destruction. To identify potential risk factors for mortality, results from pulmonary function tests conducted within the preceding 12 months, and echocardiography findings and brain natriuretic peptide (BNP) values from the day of ICU admission, were evaluated.
TDL was diagnosed on the basis of a history of present or past pulmonary tuberculosis and radiological evidence of parenchymal lung destruction, lung volume loss, or secondary bronchiectatic changes1. Active infection was defined as the presence in a blood culture or adequate sputum culture, endotracheal aspirate, or bronchoscopy sample of a pneumonia pathogen (bacteria, including tuberculosis; a virus; or a fungus). To evaluate the extent of disease involvement, baseline chest X-rays were graded on a 4-point scale (field score 1–4) using a radiographic scoring method described elsewhere4910. First, four zones were demarcated by dividing each lung into two equal-sized zones (upper and lower) on a frontal radiograph. In each of the four zones, the following scoring system was then applied: (1) 0, no abnormality; (2) 1, when less than 25% of lung parenchyma showed destructive lung lesions; and (3) 2, 3, or 4, respectively, when destroyed lung lesions involved 25%–50%, 50%–75%, or >75% of lung parenchyma. The field score was then calculated as the mean disease involvement of the two lungs. Forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) were expressed as a percentage of the predicted normal values. The FVC and FEV1 values were calculated using Korean equations, which were based on data from a non-smoking population with normal chest radiograph findings and no history of lung disease or symptoms. In these equations, the predicted value is adjusted in accordance with age, sex, height, and weight11. Cor pulmonale was diagnosed on the basis of both clinical and echocardiographic findings12. Echocardiographic signs of cor pulmonale comprised right ventricular (RV) hypertrophy or dilation accompanying high RV systolic pressure (> 35 mm Hg)1213.

3. Statistical analysis

Continuous variables are presented as the median and interquartile range. Categorical variables are presented as percentages. Continuous variables were compared using a Mann–Whitney U test. Categorical variables were compared using a chi-square or Fisher exact test. The optimal cut-off values for potential predictors of ICU mortality were selected using either the median value or locally weighted scatterplot smoothing curves14, as appropriate. Binary logistic regression analysis was performed to identify factors predicting ICU mortality. Variables with p-values of <0.20 in the univariate analysis were included in the multivariate analysis. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC), and model calibration was assessed using the Hosmer-Lemeshow test. The β coefficient values derived from multiple logistic regression were simplified to natural numbers >0, and the TDL-Vent score was calculated as the sum of these simplified values. To predict 60-day survival, Kaplan-Meier estimates were stratified according to the TDL-Vent score, and curves were compared using the log-rank test. The AUC for the TDL-Vent score predicting ICU mortality was compared with that for the APACHE II score and the SOFA score. Identification of an optimal cut-off value for the score was based on the maximum Youden's index15. All tests of significance were two-tailed, and p-values of <0.05 were considered significant. All analyses were performed using SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL, USA) and MedCalc Statistical Software version 16.8.4 (Med-Calc Software bvba, Ostend, Belgium).

Results

During the study period, 125 patients fulfilled the study inclusion criteria. Of these, 89 (71%) survived ICU admission. The remaining 36 (29%) patients died on the ICU.
Baseline characteristics of the study cohort are shown in Table 1. Nonsurvivors were older. No significant difference was found between survivors and nonsurvivors in terms of sex, body mass index, smoking status, or comorbidities. Mechanical ventilation was primarily due to pneumonia in 54% (48/89) of survivors and 69% (25/36) of non-survivors (p=0.11). Nonsurvivors had significantly higher APACHE II and SOFA scores and had a higher rate of vasopressor use within 24 hours of ICU admission. Active infection was found in 44 (35%) of the cohort, with no significant difference being found between survivors and non-survivors. The following pathogens were considered to be associated with pneumonia: methicillin-resistant Staphylococcus aureus (n=14); Acinetobacter (n=9); Mycobacterium tuberculosis (n=6); Pseudomonas (n=5); extended-spectrum beta-lactamase-producing organism (n=4); Klebsiella pneumoniae (n=3); Stenotrophomonas (n=3); and Aspergillus species (n=3). The median arterial partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio was significantly lower in non-survivors. Compared with survivors, non-survivors had numerically lower serum albumin and higher BNP, although the results were not statistically significant. Survivors and non-survivors had similar median field scores. Pulmonary function test results were available for 54 (43%) of the cohort. The median FEV1/FVC ratio was <0.70, and no significant differences between survivors and nonsurvivors were found for median FVC and FEV1. Echocardiographic findings were available for 64 (51%) of the cohort. Cor pulmonale was diagnosed in nearly half of the patients. However, the survivor and non-survivor groups showed no difference in terms of left ventricular systolic function or the proportion of patients with high RV systolic pressure. Clinical outcomes in the cohort are shown in Table 2.
Table 3 shows the results of the univariate and multivariate analyses of risk factors predicting ICU mortality. The following cut-off values were identified via inspection of locally weighted scatterplot smoothing curves: age ≥65 years, PaO2/FiO2 ratio <180, PaCO2 <52 mm Hg, serum albumin <3.0 g/dL, BNP ≥330 pg/mL, and field score ≥2 (Supplementary Figure S1). Based on the β coefficient values observed in model 1, a TDL-Vent score comprising the following factors was proposed: (1) age ≥65 years (+1 point); (2) vasopressor use (+1 point); and (3) PaO2/FiO2 ratio <180 (+1 point). This model had acceptable discrimination (AUC, 0.74) and calibration (Hosmer and Lemeshow chi-square, 14.74; p=0.06). Figure 1A shows the Kaplan-Meier survival curves, as stratified according to the TDL-Vent score. The 60-day mortality rates for scores ranging from 0 to 3 were 11%, 27%, 30%, and 77%, respectively (log-rank test, p<0.001). The AUC of the TDL-Vent score for predicting ICU mortality was 0.72 (95% confidence interval [CI], 0.63–0.80). This was larger than the AUC for the APACHE II score (0.63; 95% CI, 0.54–0.72) and SOFA score (0.62; 95% CI, 0.53–0.71) (Figure 2). The cut-off score for predicting mortality based on the maximum Youden's index was ≥2, with a sensitivity of 44% and a specificity of 93%.
In model 2, BNP was included as an additional variable in the regression model, since pulmonary hypertension is associated with poor prognosis in chronic pulmonary tuberculosis1617 and BNP is a non-invasive marker of pulmonary hypertension1819 (Table 3). In accordance with the β values in this model, the following modified TDL-Vent score was developed: (1) vasopressor use (+1 point); (2) PaO2/FiO2 ratio <180 (+2 points); and (3) BNP ≥330 pg/mL (+1 point). The model had acceptable discrimination (AUC, 0.76) and calibration (Hosmer and Lemeshow chi-square, 54.66; p=0.69). For modified TDL-Vent scores ranging from 0 to ≥3, 60-day mortality rates were 0%, 21%, 33%, and 57%, respectively (log-rank test, p=0.001) (Figure 1B). The AUC of the modified TDL-Vent score for predicting ICU mortality was 0.74 (95% CI, 0.64–0.82) (Figure 3). The cut-off score for predicting mortality was ≥2, with a sensitivity of 65% and a specificity of 71%. Table 4 shows the clinical outcomes of study patients, as stratified according to the TDL-Vent scores from models 1 and 2.

Discussion

The present analyses indicated that age, vasopressor use, PaO2/FiO2 ratio, and BNP were reliable predictors of ICU mortality in TDL patients on mechanical ventilation. These factors were therefore included in the TDL-Vent score. This simple scoring system was more effective than either the APACHE II or the SOFA score in terms of predicting ICU mortality. To our knowledge, the present study is the first to evaluate a mortality risk scoring model for TDL patients on mechanical ventilation.
Several previous investigations of patients with active pulmonary tuberculosis and acute respiratory failure reported high rates of in-hospital mortality. Risk factors associated with mortality vary between studies. However, the most frequently reported risk factors are the requirement for mechanical ventilation, sepsis, organ failure, nosocomial pneumonia, and delayed treatment32021. TDL patients presenting with acute respiratory failure have a poor prognosis. However, few studies have investigated prognostic factors in such patients. Previous studies show that AFB-positive TDL patients have more severe lung destruction and higher mortality rates than AFB-negative patients222, while a higher level of PaCO2 has been associated with increased survival2. Ryu et al.4 found that a high field score was the only predictor of reduced survival, although patients with high field scores showed higher PaCO2. The aforementioned studies investigated small cohorts of mechanically ventilated patients, and their results were inconsistent. The main strength of the present study was its relatively large cohort, which was restricted to patients requiring mechanical ventilation. This enabled the development of an individualized mortality prediction score for this specific population. An interesting and unexpected finding of the present study was the lack of association between the degree of lung destruction, tuberculosis activity, or the level of PaCO2 and increased mortality. Instead, the prognostic factors in the present cohort were age and evidence of organ failure (vasopressor use and PaO2/FiO2 <180), as suggested in other patient populations. These risk factors are consistent with those reported in previous studies of active pulmonary tuberculosis with acute respiratory failure32021, thus supporting the hypothesis that lower physiologic reserve and organ dysfunction, rather than the destroyed lung per se, are better predictors of mortality in mechanically ventilated TDL patients. A low serum albumin level also correlated with mortality in active pulmonary tuberculosis with acute respiratory failure23. In this study, nonsurvivors had lower levels of serum albumin than survivors, although this trend did not reach statistical significance. In the present cohort, the TDL-Vent score (both model 1 and model 2) was superior in terms of discriminating between survivors and non-survivors than either the APACHE II score or the SOFA score. In addition, the score from model 1 showed very high specificity in patients with the highest risk of mortality, thus limiting the possibility of misclassifying a patient as very high risk. This is crucial, as such a classification may result in the decision to withhold or withdraw life support. Lastly, the clinician is able to calculate the TDL-Vent score at the bedside, rather than relying on complicated formulas, smear tests, or chest X-rays.
In patients with TDL, pulmonary hypertension is associated with the severity of lung destruction24. In the present study, high RV systolic pressure and/or cor pulmonale were present in more than 50% of TDL patients who underwent echocardiography, although no contribution to ICU mortality was observed. Meanwhile, non-survivors had a numerically higher BNP. A BNP of ≥330 pg/mL tended to be associated with mortality and was included in the modified TDL-Vent score. These findings are consistent with the results of previous studies192526, which demonstrated that BNP levels were a prognostic factor in patients with idiopathic pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and chronic cor pulmonale. Although BNP values were available for only 96 of the 125 TDL patients, the present results suggest that further studies are warranted to confirm the utility of BNP in terms of predicting mortality in these patients.
Previous reports show that TDL can cause chronic airflow obstruction2427. Proposed mechanisms include a reduction in lung volume, a residual limitation of expiratory flow, and a decrease in ventilatory muscle strength and exercise tolerance secondary to poor nutritional status172829. The present results, in which the median FVC, FEV1, and FEV1/FVC ratio of the cohort were 48% of predicted, 40% of predicted, and 0.63, respectively, are consistent with those of previous studies. However, as did most previous reports, baseline lung function was not associated with ICU mortality.
The present study had several limitations. First, the study was retrospective and conducted at a single center. Although the study enrolled more mechanically ventilated TDL cases than previous studies, the sample size was relatively small and likely to have been responsible for some of the insignificant results. Moreover, the relatively long study period (>10 years) may have introduced selection and information bias. Second, in attempting to identify risk factors for mortality, high specificity was obtained at the expense of lower sensitivity, as a substantial proportion of patients who died did not have a high TDL-Vent score. Third, a substantial number of patients were excluded from the echocardiography and pulmonary function analyses due to missing data. The inclusion of these patients might have influenced the study results. Lastly, the present study provided a development set only, and the results therefore require independent validation.
In conclusion, the TDL-Vent score is a simple model that may facilitate the prediction of mortality in TDL patients on mechanical ventilation. Prospective validation of the TDL-Vent score in a larger cohort is warranted.

Acknowledgments

This work was supported by a 2017 clinical research grant from Pusan National University Hospital. The funders had no role in study design, data collection and analysis, preparation of the manuscript, or decision to publish.

Notes

Authors' Contributions: Conceptualization: Kim WY, Lee K. Methodology: Jo EJ, Eom JS, Mok J, Kim KU, Park HK, Lee MK. Formal analysis: Kim WY. Data curation: Kim WY, Kim MH. Writing – original draft preparation: Kim WY, Kim MH. Writing % review and editing: Jo EJ, Eom JS, Mok J, Kim KU, Park HK, Lee MK, Lee K. Approval of final manuscript: all authors.

Conflicts of Interest: No potential conflict of interest relevant to this article was reported.

References

1. Bobrowitz ID, Rodescu D, Marcus H, Abeles H. The destroyed tuberculous lung. Scand J Respir Dis. 1974; 55:82–88. PMID: 4854707.
2. Park JH, Na JO, Kim EK, Lim CM, Shim TS, Lee SD, et al. The prognosis of respiratory failure in patients with tuberculous destroyed lung. Int J Tuberc Lung Dis. 2001; 5:963–967. PMID: 11605892.
3. Ryu YJ, Koh WJ, Kang EH, Suh GY, Chung MP, Kim H, et al. Prognostic factors in pulmonary tuberculosis requiring mechanical ventilation for acute respiratory failure. Respirology. 2007; 12:406–411. PMID: 17539846.
crossref
4. Ryu YJ, Lee JH, Chun EM, Chang JH, Shim SS. Clinical outcomes and prognostic factors in patients with tuberculous destroyed lung. Int J Tuberc Lung Dis. 2011; 15:246–250. PMID: 21219689.
5. Chakhaia T, Magee MJ, Kempker RR, Gegia M, Goginashvili L, Nanava U, et al. High utility of contact investigation for latent and active tuberculosis case detection among the contacts: a retrospective cohort study in Tbilisi, Georgia, 2010–2011. PLoS One. 2014; 9:e111773. PMID: 25379809.
crossref
6. Calligaro GL, Theron G, Khalfey H, Peter J, Meldau R, Matinyenya B, et al. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial. Lancet Respir Med. 2015; 3:621–630. PMID: 26208996.
crossref
7. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13:818–829. PMID: 3928249.
8. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996; 22:707–710. PMID: 8844239.
9. Wong KT, Antonio GE, Hui DS, Lee N, Yuen EH, Wu A, et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology. 2003; 228:401–406. PMID: 12759474.
crossref
10. Muller NL, Ooi GC, Khong PL, Nicolaou S. Severe acute respiratory syndrome: radiographic and CT findings. AJR Am J Roentgenol. 2003; 181:3–8. PMID: 12818821.
11. Choi JK, Paek D, Lee JO. Normal predictive values of spirometry in Korean population. Tuberc Respir Dis. 2005; 58:230–242.
crossref
12. Weitzenblum E. Chronic cor pulmonale. Heart. 2003; 89:225–230. PMID: 12527688.
crossref
13. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003; 167:735–740. PMID: 12480614.
crossref
14. Cleveland WS, Grosse E, Shyu WM. Local regression models. In : Chambers JM, Hastie TJ, editors. Statistical models in S. Pacific Grove: Wadsworth & Brooks/Cole;1992. p. 309–376.
15. Perkins NJ, Schisterman EF. The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006; 163:670–675. PMID: 16410346.
crossref
16. Bishop JM, Cross KW. Physiological variables and mortality in patients with various categories of chronic respiratory disease. Bull Eur Physiopathol Respir. 1984; 20:495–500. PMID: 6440605.
17. Lee JH, Chang JH. Lung function in patients with chronic airflow obstruction due to tuberculous destroyed lung. Respir Med. 2003; 97:1237–1242. PMID: 14635980.
crossref
18. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008; 32:1371–1385. PMID: 18978137.
crossref
19. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122:164–172. PMID: 20585012.
20. Lee PL, Jerng JS, Chang YL, Chen CF, Hsueh PR, Yu CJ, et al. Patient mortality of active pulmonary tuberculosis requiring mechanical ventilation. Eur Respir J. 2003; 22:141–147. PMID: 12882464.
crossref
21. Erbes R, Oettel K, Raffenberg M, Mauch H, Schmidt-Ioanas M, Lode H. Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. Eur Respir J. 2006; 27:1223–1228. PMID: 16481385.
crossref
22. Kim S, Kim H, Kim WJ, Lee SJ, Hong Y, Lee HY, et al. Mortality and predictors in pulmonary tuberculosis with respiratory failure requiring mechanical ventilation. Int J Tuberc Lung Dis. 2016; 20:524–529. PMID: 26970163.
crossref
23. Zahar JR, Azoulay E, Klement E, De Lassence A, Lucet JC, Regnier B, et al. Delayed treatment contributes to mortality in ICU patients with severe active pulmonary tuberculosis and acute respiratory failure. Intensive Care Med. 2001; 27:513–520. PMID: 11355119.
crossref
24. Jo YS, Park JH, Lee JK, Heo EY, Chung HS, Kim DK. Risk factors for pulmonary arterial hypertension in patients with tuberculosis-destroyed lungs and their clinical characteristics compared with patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017; 12:2433–2443. PMID: 28860738.
crossref
25. Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med. 2009; 103:180–186. PMID: 19097877.
crossref
26. Park SY, Lee CY, Kim C, Jang SH, Park YB, Park S, et al. One-year prognosis and the role of brain natriuretic peptide levels in patients with chronic cor pulmonale. J Korean Med Sci. 2015; 30:442–449. PMID: 25829812.
crossref
27. Rhee CK, Yoo KH, Lee JH, Park MJ, Kim WJ, Park YB, et al. Clinical characteristics of patients with tuberculosis-destroyed lung. Int J Tuberc Lung Dis. 2013; 17:67–75. PMID: 23232006.
crossref
28. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax. 2000; 55:32–38. PMID: 10607799.
crossref
29. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, et al. Pulmonary impairment after tuberculosis. Chest. 2007; 131:1817–1824. PMID: 17400690.
crossref

Supplementary Material

Supplementary material can be found in the journal homepage (http://www.e-trd.org).
Supplementary Figure S1. Locally weighted scatterplot smoothing curves.

Supplementary Figure S1

Locally weighted scatterplot smoothing curves. ICU: intensive care unit; PaO2: arterial partial pressure of oxygen; FiO2: fraction of inspired oxygen; PaCO2: arterial partial pressure of carbon dioxide; BNP: brain natriuretic peptide.
trd-81-247-s001.pdf
Figure 1

Kaplan-Meier survival curves, as stratified according to the TDL-Vent score (A) and the modified TDL-Vent score (B). TDL-Vent: tuberculous destroyed lung on mechanical ventilation; ICU: intensive care unit.

trd-81-247-g001
Figure 2

Receiver operating characteristic curves of the TDL-Vent, APACHE II, and SOFA scores for predicting ICU mortality. TDL-Vent: tuberculous destroyed lung on mechanical ventilation; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; ICU: intensive care unit; AUC: area under the receiver operating characteristic curve.

trd-81-247-g002
Figure 3

Receiver operating characteristic curves of the modified TDL-Vent, APACHE II, and SOFA scores for predicting ICU mortality. TDL-Vent: tuberculous destroyed lung on mechanical ventilation; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; ICU: intensive care unit; AUC: area under the receiver operating characteristic curve.

trd-81-247-g003
Table 1

Baseline characteristics of the study cohort

trd-81-247-i001
Variable Total (n=125) Survivors (n=89) Nonsurvivors (n=36) p-value
Age, yr 66 (57–74) 64 (56–72) 72 (62–76) 0.03
Male sex 104 (83) 72 (81) 32 (89) 0.28
Body mass index, kg/m2 19.5 (16.7–22.2) 19.9 (17.1–22.3) 18.8 (15.1–22.2) 0.18
Smoking 0.43
 Never smoker 66 (53) 49 (55) 17 (47)
 Ever smoker 59 (47) 40 (45) 19 (53)
Comorbidity
 Diabetes 25 (20) 17 (19) 8 (22) 0.69
 Hypertension 31 (25) 25 (28) 6 (17) 0.18
 Heart disease 30 (24) 21 (24) 9 (25) 0.87
 Cerebrovascular disease 10 (8) 5 (6) 5 (14) 0.15
 Chronic lung disease 53 (42) 38 (43) 15 (42) 0.92
 Chronic liver disease 8 (6) 7 (8) 1 (3) 0.44
 Chronic kidney disease 5 (4) 4 (5) 1 (3) >0.99
 Malignancy 13 (10) 10 (11) 3 (8) 0.76
Major diagnoses leading to MV
 Pneumonia 73 (58) 48 (54) 25 (69) 0.11
 Acute exacerbation 20 (16) 16 (18) 4 (11) 0.34
 Hemoptysis 19 (15) 12 (14) 7 (19) 0.40
Severity of illness
 APACHE II score 19 (15–24) 18 (15–23) 21 (18–28) 0.02
 SOFA score 8 (4–11) 7 (4–10) 9 (7–11) 0.03
Vasopressor use 58 (46) 33 (37) 25 (69) 0.001
Renal replacement therapy 10 (8) 7 (8) 3 (8) >0.99
Active infection 44 (35) 31 (35) 13 (36) 0.89
Laboratory data
 PaO2/FiO2 176 (120–241) 197 (138–303) 139 (103–182) <0.001
 PaCO2, mm Hg 52 (42–65) 54 (42–64) 51 (39–70) 0.71
 Platelet count, 1,000 cells/mm3 224 (170–289) 224 (170–278) 228 (161–300) 0.66
 Total bilirubin, mg/dL 0.7 (0.5–1.1) 0.7 (0.5–1.0) 0.6 (0.5–1.1) 0.55
 Creatinine, mg/dL 0.8 (0.6–1.0) 0.7 (0.6–1.0) 0.8 (0.6–1.1) 0.55
 Albumin, g/dL 3.0 (2.6–3.7) 3.1 (2.7–3.8) 2.9 (2.5–3.6) 0.28
 BNP, pg/mL* (n=70/26) 333 (101–797) 312 (89–669) 479 (210–908) 0.15
Field score 2 (2–2) 2 (2–2) 2 (2–2) 0.87
Spirometric values (n=40/14)
 FVC, % of predicted 48 (35–59) 46 (35–58) 54 (36–67) 0.22
 FEV1, % of predicted 40 (29–59) 37 (28–55) 46 (37–70) 0.21
 FEV1/FVC 0.63 (0.53–0.82) 0.63 (0.54–0.80) 0.65 (0.53–0.88) 0.84
Echocardiography (n=47/17)
 Ejection fraction, % 60 (56–60) 60 (56–63) 60 (53–60) 0.16
 High RVSP§, || (n=45/14) 35 (59) 26 (58) 9 (64) 0.67
 Cor pulmonale (n=46/15) 26 (43) 20 (44) 6 (40) 0.81

Values are presented as the median (interquartile range) or number (%).

*No. of survivors/nonsurvivors=70/26. No. of survivors/nonsurvivos=40/14. No. of survivors/nonsurvivos=47/17. §RVSP >35 mm Hg. No. of survivors/nonsurvivos=45/14. No. of survivors/nonsurvivos=46/15.

MV: mechanical ventilation; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; PaO2: arterial partial pressure of oxygen; FiO2: fraction of inspired oxygen; PaCO2: arterial partial pressure of carbon dioxide; BNP: brain natriuretic peptide; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; RVSP: right ventricular systolic pressure.

Table 2

Clinical outcomes in the study cohort

trd-81-247-i002
Variable Total (n=125)
MV duration, day 8 (5–17)
Tracheostomy during ICU stay 34 (27)
Length of ICU stay, day 11 (7–18)
Length of hospital stay, day 20 (12–43)
Mortality
 ICU 36 (29)
 In-hospital 46 (37)
 28-Day 38 (30)
 60-Day 43 (34)

Values are presented as the median (interquartile range) or number (%).

MV: mechanical ventilation; ICU: intensive care unit.

Table 3

Factors included in the TDL-Vent score

trd-81-247-i003
Variable Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value β value
Model 1*
 Age ≥65 yr 1.81 (0.82–4.02) 0.15 1.63 (0.68–3.95) 0.28 0.49
 Pneumonia 1.94 (0.85–4.42) 0.11 - - -
 Vasopressor use 3.86 (1.68–8.84) 0.001 3.47 (1.41–8.54) 0.007 1.24
 PaO2/FiO2 <180 4.03 (1.70–9.55) 0.002 3.41 (1.34–8.65) 0.01 1.23
 PaCO2 <52 mm Hg 1.31 (0.60–2.84) 0.50 - - -
 Albumin <3.0 g/dL 1.88 (0.86–4.12) 0.12 - - -
 Field score ≥2 1.01 (0.40–2.57) 0.98 - - -
Model 2
 Age ≥65 yr 1.81 (0.82–4.02) 0.15 - - -
 Pneumonia 1.94 (0.85–4.42) 0.11 - - -
 Vasopressor use 3.86 (1.68–8.84) 0.001 3.13 (1.10–8.88) 0.03 1.14
 PaO2/FiO2 <180 4.03 (1.70–9.55) 0.002 4.61 (1.51–14.10) 0.007 1.53
 PaCO2 <52 mm Hg 1.31 (0.60–2.84) 0.50 - - -
 Albumin <3.0 g/dL 1.88 (0.86–4.12) 0.12 - - -
 BNP ≥330 pg/mL 1.69 (0.68–4.25) 0.26 1.96 (0.70–5.45) 0.2 0.67
 Field score ≥2 1.01 (0.40–2.57) 0.98 - - -

*Variables with p-values of <0.20 in the univariate analysis were included in the multivariate analysis. BNP and the other variables with p-values of <0.20 in the univariate analysis were included in the multivariate analysis.

TDL-Vent: tuberculous destroyed lung on mechanical ventilation; OR: odds ratio; CI: confidence interval; PaO2: arterial partial pressure of oxygen; FiO2: fraction of inspired oxygen; PaCO2: arterial partial pressure of carbon dioxide; BNP: brain natriuretic peptide.

Table 4

Clinical outcomes according to TDL-Vent score

trd-81-247-i004
Variable TDL-Vent score p-value
Score 0 (n=19) Score 1 (n=44) Score 2 (n=40) Score 3 (n=22)
Model 1
 MV-free days at day 60 52 (35–56) 40 (0–53) 19 (0–53) 0 (0–0) <0.001
 ICU mortality 1 (5) 11 (25) 8 (20) 16 (73) <0.001
 In-hospital mortality 2 (11) 12 (27) 14 (35) 18 (82) <0.001
 60-Day mortality 2 (11) 12 (27) 12 (30) 17 (77) <0.001
Model 2 (n=96)* Score 0 (n=13) Score 1 (n=19) Score 2 (n=27) Score 3–4 (n=37)
 MV-free days at day 60 56 (52–57) 47 (0–53) 0 (0–48) 0 (0–48) 0.001
 ICU mortality 0 2 (11) 7 (26) 17 (46) 0.003
 In-hospital mortality 0 4 (21) 9 (33) 22 (60) <0.001
 60-Day mortality 0 4 (21) 9 (33) 21 (57) 0.001

Values are presented as the median (interquartile range) or number (%).

*Patients without BNP values were excluded.

TDL-Vent: tuberculous destroyed lung on mechanical ventilation; MV: mechanical ventilation; ICU: intensive care unit; BNP: brain natriuretic peptide.

TOOLS
Similar articles